- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
AccuImage qualifies for Over-the-Counter trading
AccuImage qualifies for Over-the-Counter tradingThe OTC Bulletin Board has authorized AccuImage Diagnostics to begin trading its stock on the OTCBB under "AIDP" as of Oct. 23. The San Francisco-based imaging company counts year-to-date income
AccuImage qualifies for Over-the-Counter trading
The OTC Bulletin Board has authorized AccuImage Diagnostics to begin trading its stock on the OTCBB under "AIDP" as of Oct. 23. The San Francisco-based imaging company counts year-to-date income of $252,096 and revenue of $2.3 million and claims that its revenue has more than doubled over the same period in 1999. AccuImage develops three-dimensional visualization software, including products that enable 3-D Web-based PACS review, and digital image distribution and archiving technologies. The company is actively pursuing strategic alliances with equipment vendors and broadband providers.
- Search Again
- Return To HNN Homepage
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.
